How an anticoagulant reversal agent is changing the treatment conversation

Sponsored by Boehringer Ingelheim Pty Ltd

The availability of an anticoagulant reversal agent in Australia has changed the conversation about treatment choices for patients and removed a concern for clinicians, an expert says. Speaking to the limbic following a breakfast symposium sponsored by Boehringer Ingelheim at the recent Cardiac Society for Australia and New Zealand’s annual congress Professor John Amerena a ...

Already a member?

Login to keep reading.

© 2021 the limbic